Tarl W. Prow

6.1k total citations · 2 hit papers
127 papers, 4.5k citations indexed

About

Tarl W. Prow is a scholar working on Dermatology, Molecular Biology and Pharmaceutical Science. According to data from OpenAlex, Tarl W. Prow has authored 127 papers receiving a total of 4.5k indexed citations (citations by other indexed papers that have themselves been cited), including 37 papers in Dermatology, 35 papers in Molecular Biology and 34 papers in Pharmaceutical Science. Recurrent topics in Tarl W. Prow's work include Advancements in Transdermal Drug Delivery (33 papers), Cutaneous Melanoma Detection and Management (25 papers) and Skin Protection and Aging (20 papers). Tarl W. Prow is often cited by papers focused on Advancements in Transdermal Drug Delivery (33 papers), Cutaneous Melanoma Detection and Management (25 papers) and Skin Protection and Aging (20 papers). Tarl W. Prow collaborates with scholars based in Australia, United States and United Kingdom. Tarl W. Prow's co-authors include Michael S. Roberts, Miko Yamada, H. Peter Soyer, Jeffrey E. Grice, Lynlee L. Lin, Xianfeng Chen, Anthony P. Raphael, M. A. F. Kendall, Germain J. P. Fernando and Michael L. Crichton and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and PLoS ONE.

In The Last Decade

Tarl W. Prow

122 papers receiving 4.3k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Nanoparticles and microparticles for skin drug delivery

2011 610 citations Tarl W. Prow, Jeffrey E. Grice et al. Advanced Drug Delivery Reviews profile →
Health-related toxicity of emerging per- and polyfluoroalkyl substances: Comparison to legacy PFOS and PFOA

2022 189 citations Miko Yamada, Judith M. Ford et al. Environmental Research profile →

Peers

Countries citing papers authored by Tarl W. Prow

Since Specialization

Citations

This map shows the geographic impact of Tarl W. Prow's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Tarl W. Prow with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Tarl W. Prow more than expected).

Fields of papers citing papers by Tarl W. Prow

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Tarl W. Prow. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Tarl W. Prow. The network helps show where Tarl W. Prow may publish in the future.

Co-authorship network of co-authors of Tarl W. Prow

This figure shows the co-authorship network connecting the top 25 collaborators of Tarl W. Prow. A scholar is included among the top collaborators of Tarl W. Prow based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Tarl W. Prow. Tarl W. Prow is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Dermal permeation of perfluoroalkyl substances in human skin – An in-vitro study 2025 ·Chemosphere ·(unknown), (unknown), Samuel D. Bradley, Mark H. Moore, Miko Yamada, (unknown), Tarl W. Prow, Albert L. Juhasz, Phong K. Thai	0
2	MicroRNA Expression Profiling of Cutaneous Squamous Cell Carcinomas and Precursor Lesions 2024 ·SHILAP Revista de lepidopterología ·(unknown), (unknown), (unknown), Miko Yamada, (unknown), Kasturee Jagirdar, Tarl W. Prow, H. Peter Soyer, Mitchell Stark	0
3	Skin Cancer Excisions and Histopathology Outcomes When Following a Contemporary Population-Based Cohort Longitudinally with 3D Total-Body Photography 2023 ·SHILAP Revista de lepidopterología ·H. Peter Soyer, (unknown), (unknown), Caitlin Horsham, (unknown), (unknown), Helmut Schaider, Joanne F. Aitken, Richard A. Sturm, Tarl W. Prow, Scott W. Menzies, Monika Janda	3
4	The Experience of 3D Total-Body Photography to Monitor Nevi: Results From an Australian General Population-Based Cohort Study 2022 ·JMIR Dermatology ·Caitlin Horsham, (unknown), (unknown), (unknown), (unknown), Adèle C. Green, Helmut Schaider, Joanne F. Aitken, Richard A. Sturm, Tarl W. Prow, H. Peter Soyer, Monika Janda	9
5	Health-related toxicity of emerging per- and polyfluoroalkyl substances: Comparison to legacy PFOS and PFOA breakdown → 2022 ·Environmental Research ·(unknown), Miko Yamada, Judith M. Ford, Gary Owens, Tarl W. Prow, Albert L. Juhasz	189
6	A first-in-human study of BLZ-100 (tozuleristide) demonstrates tolerability and safety in skin cancer patients 2021 ·Contemporary Clinical Trials Communications ·Miko Yamada, Dennis M. Miller, Melinda Lowe, Casey Rowe, (unknown), H. Peter Soyer, Kelly Byrnes-Blake, Julia Parrish-Novak, Laura Ishak, James M. Olson, Gordon Brandt, Paul Griffin, Lynda Spelman, Tarl W. Prow	25
7	‘Mind your Moles’ study: protocol of a prospective cohort study of melanocytic naevi 2018 ·BMJ Open ·(unknown), Monika Janda, Joanne F. Aitken, David L. Duffy, Scott W. Menzies, Richard A. Sturm, Helmut Schaider, Brigid Betz‐Stablein, Tarl W. Prow, H. Peter Soyer, Adèle C. Green	19
8	Concurrent Reflectance Confocal Microscopy and Laser Doppler Flowmetry to Improve Skin Cancer Imaging: A Monte Carlo Model and Experimental Validation 2016 ·Sensors ·Alireza Mowla, Thomas Taimre, Yah Leng Lim, Karl Bertling, Stephen J. Wilson, Tarl W. Prow, H. Peter Soyer, Aleksandar D. Rakić	12
9	Fractional laser‐assisted drug uptake: Impact of time‐related topical application to achieve enhanced delivery 2016 ·Lasers in Surgery and Medicine ·Christina Alette Banzhaf, Daniel Thaysen‐Petersen, Christiane Bay, Peter A. Philipsen, Mette Mogensen, Tarl W. Prow, Merete Hædersdal	38
10	Effective cutaneous vaccination using an inactivated chikungunya virus vaccine delivered by Foroderm 2015 ·Vaccine ·Penny A. Rudd, Anthony P. Raphael, Miko Yamada, (unknown), Joy Gardner, Thuy T. Le, Natalie A. Prow, Nhung Dang, Wayne A. Schroder, Tarl W. Prow, Andreas Suhrbier	10
11	Enhanced Delivery of Nano- and Submicron Particles Using Elongated Microparticles 2015 ·Current Drug Delivery ·Anthony P. Raphael, (unknown), David S. Liu, Tarl W. Prow	8
12	Recent Advances in Physical Delivery Enhancement of Topical Drugs 2015 ·Current Pharmaceutical Design ·Anthony P. Raphael, Olivia Wright, Heather A. E. Benson, Tarl W. Prow	13
13	Microneedle Enhanced Delivery of Cosmeceutically Relevant Peptides in Human Skin 2014 ·PLoS ONE ·Yousuf Mohammed, Miko Yamada, Lynlee L. Lin, Jeffrey E. Grice, Michael S. Roberts, Anthony P. Raphael, Heather A. E. Benson, Tarl W. Prow	71
14	Comparative analysis of UV-induced DNA damage and metabolic deterioration in skin by gamma-H2AX immunohistochemistry and NAD(P)H imaging 2011 ·Australasian Journal of Dermatology ·Les Baillie, Tarl W. Prow, H. Peter Soyer	1
15	Non-invasive assessment of skin ageing 2011 ·Australasian Journal of Dermatology ·(unknown), Tarl W. Prow, Lynlee L. Lin, (unknown), Emily Chai, H. Peter Soyer	2
16	Nanoparticles and microparticles for skin drug delivery breakdown → 2011 ·Advanced Drug Delivery Reviews ·Tarl W. Prow, Jeffrey E. Grice, Lynlee L. Lin, (unknown), Margaret K. Butler, Wolfgang Becker, Elisabeth M.T. Wurm, Corinne Yoong, Thomas A. Robertson, H. Peter Soyer, Michael S. Roberts	610
17	Nanoparticle-delivered biosensor for reactive oxygen species in diabetes 2008 ·Vision Research ·Tarl W. Prow, Imran Ahmed Bhutto, Rhonda Grebe, Koichi Uno, Carol Merges, D. Scott McLeod, Gerard A. Lutty	19
18	Characterization of Vascular Precursors in Developing Human Retina 2007 ·Investigative Ophthalmology & Visual Science ·Gerard A. Lutty, Takuya Hasegawa, Tarl W. Prow, C. Merges, D. Scott McLeod	2
19	Novel Therapeutic Gene Regulation by Genetic Biosensor Tethered to Magnetic Nanoparticles for the Detection and Treatment of Retinopathy of Prematurity 2005 ·Investigative Ophthalmology & Visual Science ·Tarl W. Prow, Rhonda Grebe, C. Merges, D. Scott McLeod, James F. Leary, (unknown)	3
20	Development of a novel targeted nanoparticle gene therapy strategy for the treatment of hepatitis C virus infection 2002 ·Cytometry ·Tarl W. Prow, René Rijnbrand, James F. Leary	1

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact